Fatal Serotonin Syndrome following a Combined Overdose of Moclobemide,Clomipramine and Fluoxetine

Fitton A. , Faulds D. , Goa K.L. Moclobemide, A review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992; 43: 561–596.

Stokes P.E. Fluoxetine: a five-year review. Clin Therap 1993; 15: 216–243.

Vine R. , Norman T.R. , Burrows G.D. A case of moclobemide overdose. International Clin Psychopharmacol 1988; 3: 325–326.

Moll E. , Hetzel W. Moclobemide (RO 11-1163) safety in depressed patients. Acta Psychiat Scand 1990; 360 (suppl): 69–70.

Myrenfors P.G. , Eriksson T. , Sandstedt G.S. , Sjoberg G. Moclobemide overdose. J Intern Med 1993; 233: 113–115.

Hackett L.P. , Joyce D.A. , Hall R.W. , Dusci L.J. , Ilett K.F. Disposition and clinical effects of moclobemide and three of its metabolites following overdose. Drug Invest 1993; 5: 281–284.

Neuvonen P.J. , Pohjola-Sintonen S. , Tacke U. , Vuori E. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdose. Lancet 1993; 342: 1419.

Brodribb T.R. , Downey M. , Gilbar P.J. Efficacy and adverse effects of moclobemide. Lancet 1994; 343: 475.

Kemp J. , Ilett K.F. , Booth J. , Hackett L.P. Excretion of doxepin and N-desmethyldoxepin in human milk. Br J Clin Pharmac 1985; 20: 497–499.

Geschke R. , Korner J. , Eggers H. Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by high-performance liquid chromatography. J Chromatogr 1987; 420: 111–120.

Sternbach H. The serotonin syndrome. Am J Psychiat 1991; 149: 705–713.

Nierenberg D.W. , Semprebon B.S. The central nervous system serotonin syndrome. Clin Pharmacol Ther 1993; 53: 84–88.

Tackley R.M. , Tregaskis B. Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction. Anaesthesia 1987; 42: 760–763.

Guentert T.W. , Tucker G. , Korn A. , Pfefen J.P. , Haefelfinger P. , Schoerlin M.P. Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams three times daily for 15 days. Acta Psychiat Scand 1990; 82 (Suppl 360): 91–93.

Balant-Gorgia A.E. , Balant L.P. , Garrone G. High blood concentrations of imipramine or clomipramine and therapeutic failure; a case report study using drug monitoring data. Therap Drug Monit 1989; 11: 415–420.

Kelly M.W. , Perry PJ , Holstad SG , Garvey MJ . Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Therap Drug Monit 1989; 11: 165–170.

Tehan B. , Hardern R. , Bodenham A. Hyperthermia associated with 3, 4-methylenedioxyethylamphetamine (“Eve”). Anaesthesia 1993; 48: 507–510.

Padkin A. Treating MDMA (“Ecstasy”) toxicity. Anaesthesia 1994; 49: 259.

Graham P.M. , Potter J.M. , Matterson J.W. Combination monoamine oxidase inhibitor/tricyclic antidepressant interaction. Lancet 1982; ii: 440.

Stern T.A. , Schwartz J.H. , Schuster J.L. Catastrophic illness associated with the combination of clomipramine, phenelzine and chlorpromazine. Annals Clin Psychiat 1992; 4: 81–85.

Mallampalli R. , Pentel P.R. , Anderson D.C. Nonreactive pupils due to monoamine oxidase inhibitor overdose. Crit Care Med 1987; 15: 536–537.

Spigset O. , Mjorndal T. , Lovheim O. Serotonin syndrome caused by moclobemide-clomipramine interaction. Br Med J 1993; 306: 248.

Bakish D. , Hooper C.L. , West D.L. Moclobemide and specific serotonin reuptake inhibitor combination treatment of resistant anxiety and depressive disorders. Human Psychopharmacology (in press).

Delini-Stula A. , Dingemanse J. , Mikkelsen H. Pharmacological interactions of selective 5-HT reuptake inhibitors and moclobemide—reversible MAO-A inhibitor, and the phenomenon of 5-HT syndrome. J Clin Psychopharm (in press).